Safety and effectiveness of a computerized Subcutaneous insulin program to treat inpatient hyperglycemia

Rattan Juneja, Adam A. Golas, Joni Carroll, Deborah Nelson, Victor J. Abad, Corbin P. Roudebush, Samuel J. Flanders

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: This proof of concept study was designed to evaluate the safety and effectiveness of a computerized insulin program, the Clarian GlucoStabilizer" Subcutaneous Insulin Program (CGS-SQ). This paper discusses the CGS-SQ's impact on the glycemic control of hospitalized patients with hyperglycemia. Methods: Patients at Methodist and Indiana University Hospitals requiring subcutaneous insulin were treated using the CGS-SQ. This program calculates subcutaneous bolus insulin doses based on the current blood glucose (BG), using an insulin sensitivity factor, the number of grams of carbohydrates eaten, and an insulin-to-carbohydrate ratio, with a goal of maintaining the patient's BG in a prespecified target range. The target range, insulin sensitivity factor, and insulin-to-carbohydrate ratio are established by the physician. Results: From April 2006 to September 2007, the CGS-SQ treated 1772 patients at Methodist and Indiana University Hospitals, with 46,575 BGs in its database. For these patients, the average BG was 158.3 mg/dl, 40.5% percent of BGs were in the default target range of 100-150 mg/dl, and 69.8% were in the wider range of 70-180 mg/dl. The hypoglycemia (BG <40 mg/dl) rate was 0.18%. Conclusions: The CGS-SQ provided a means to deliver insulin in a standardized manner, resulting in satisfactory BG control with a low hypoglycemia rate, thus serving as a tool for safe and effective insulin therapy for hospitalized patients.

Original languageEnglish
Pages (from-to)384-391
Number of pages8
JournalJournal of diabetes science and technology
Volume2
Issue number3
StatePublished - May 2008

Fingerprint

Insulin
Hyperglycemia
Inpatients
Safety
Blood Glucose
Glucose
Blood
Carbohydrates
Hypoglycemia
Insulin Resistance
Databases
Physicians

Keywords

  • Computers
  • Diabetes
  • Dosing
  • Hyperglycemia
  • Insulin
  • Protocol
  • Subcutaneous

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Bioengineering
  • Biomedical Engineering

Cite this

Juneja, R., Golas, A. A., Carroll, J., Nelson, D., Abad, V. J., Roudebush, C. P., & Flanders, S. J. (2008). Safety and effectiveness of a computerized Subcutaneous insulin program to treat inpatient hyperglycemia. Journal of diabetes science and technology, 2(3), 384-391.

Safety and effectiveness of a computerized Subcutaneous insulin program to treat inpatient hyperglycemia. / Juneja, Rattan; Golas, Adam A.; Carroll, Joni; Nelson, Deborah; Abad, Victor J.; Roudebush, Corbin P.; Flanders, Samuel J.

In: Journal of diabetes science and technology, Vol. 2, No. 3, 05.2008, p. 384-391.

Research output: Contribution to journalArticle

Juneja, R, Golas, AA, Carroll, J, Nelson, D, Abad, VJ, Roudebush, CP & Flanders, SJ 2008, 'Safety and effectiveness of a computerized Subcutaneous insulin program to treat inpatient hyperglycemia', Journal of diabetes science and technology, vol. 2, no. 3, pp. 384-391.
Juneja, Rattan ; Golas, Adam A. ; Carroll, Joni ; Nelson, Deborah ; Abad, Victor J. ; Roudebush, Corbin P. ; Flanders, Samuel J. / Safety and effectiveness of a computerized Subcutaneous insulin program to treat inpatient hyperglycemia. In: Journal of diabetes science and technology. 2008 ; Vol. 2, No. 3. pp. 384-391.
@article{9ab92e9149bd46fe81915e40f83fd8d3,
title = "Safety and effectiveness of a computerized Subcutaneous insulin program to treat inpatient hyperglycemia",
abstract = "Background: This proof of concept study was designed to evaluate the safety and effectiveness of a computerized insulin program, the Clarian GlucoStabilizer{"} Subcutaneous Insulin Program (CGS-SQ). This paper discusses the CGS-SQ's impact on the glycemic control of hospitalized patients with hyperglycemia. Methods: Patients at Methodist and Indiana University Hospitals requiring subcutaneous insulin were treated using the CGS-SQ. This program calculates subcutaneous bolus insulin doses based on the current blood glucose (BG), using an insulin sensitivity factor, the number of grams of carbohydrates eaten, and an insulin-to-carbohydrate ratio, with a goal of maintaining the patient's BG in a prespecified target range. The target range, insulin sensitivity factor, and insulin-to-carbohydrate ratio are established by the physician. Results: From April 2006 to September 2007, the CGS-SQ treated 1772 patients at Methodist and Indiana University Hospitals, with 46,575 BGs in its database. For these patients, the average BG was 158.3 mg/dl, 40.5{\%} percent of BGs were in the default target range of 100-150 mg/dl, and 69.8{\%} were in the wider range of 70-180 mg/dl. The hypoglycemia (BG <40 mg/dl) rate was 0.18{\%}. Conclusions: The CGS-SQ provided a means to deliver insulin in a standardized manner, resulting in satisfactory BG control with a low hypoglycemia rate, thus serving as a tool for safe and effective insulin therapy for hospitalized patients.",
keywords = "Computers, Diabetes, Dosing, Hyperglycemia, Insulin, Protocol, Subcutaneous",
author = "Rattan Juneja and Golas, {Adam A.} and Joni Carroll and Deborah Nelson and Abad, {Victor J.} and Roudebush, {Corbin P.} and Flanders, {Samuel J.}",
year = "2008",
month = "5",
language = "English",
volume = "2",
pages = "384--391",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "3",

}

TY - JOUR

T1 - Safety and effectiveness of a computerized Subcutaneous insulin program to treat inpatient hyperglycemia

AU - Juneja, Rattan

AU - Golas, Adam A.

AU - Carroll, Joni

AU - Nelson, Deborah

AU - Abad, Victor J.

AU - Roudebush, Corbin P.

AU - Flanders, Samuel J.

PY - 2008/5

Y1 - 2008/5

N2 - Background: This proof of concept study was designed to evaluate the safety and effectiveness of a computerized insulin program, the Clarian GlucoStabilizer" Subcutaneous Insulin Program (CGS-SQ). This paper discusses the CGS-SQ's impact on the glycemic control of hospitalized patients with hyperglycemia. Methods: Patients at Methodist and Indiana University Hospitals requiring subcutaneous insulin were treated using the CGS-SQ. This program calculates subcutaneous bolus insulin doses based on the current blood glucose (BG), using an insulin sensitivity factor, the number of grams of carbohydrates eaten, and an insulin-to-carbohydrate ratio, with a goal of maintaining the patient's BG in a prespecified target range. The target range, insulin sensitivity factor, and insulin-to-carbohydrate ratio are established by the physician. Results: From April 2006 to September 2007, the CGS-SQ treated 1772 patients at Methodist and Indiana University Hospitals, with 46,575 BGs in its database. For these patients, the average BG was 158.3 mg/dl, 40.5% percent of BGs were in the default target range of 100-150 mg/dl, and 69.8% were in the wider range of 70-180 mg/dl. The hypoglycemia (BG <40 mg/dl) rate was 0.18%. Conclusions: The CGS-SQ provided a means to deliver insulin in a standardized manner, resulting in satisfactory BG control with a low hypoglycemia rate, thus serving as a tool for safe and effective insulin therapy for hospitalized patients.

AB - Background: This proof of concept study was designed to evaluate the safety and effectiveness of a computerized insulin program, the Clarian GlucoStabilizer" Subcutaneous Insulin Program (CGS-SQ). This paper discusses the CGS-SQ's impact on the glycemic control of hospitalized patients with hyperglycemia. Methods: Patients at Methodist and Indiana University Hospitals requiring subcutaneous insulin were treated using the CGS-SQ. This program calculates subcutaneous bolus insulin doses based on the current blood glucose (BG), using an insulin sensitivity factor, the number of grams of carbohydrates eaten, and an insulin-to-carbohydrate ratio, with a goal of maintaining the patient's BG in a prespecified target range. The target range, insulin sensitivity factor, and insulin-to-carbohydrate ratio are established by the physician. Results: From April 2006 to September 2007, the CGS-SQ treated 1772 patients at Methodist and Indiana University Hospitals, with 46,575 BGs in its database. For these patients, the average BG was 158.3 mg/dl, 40.5% percent of BGs were in the default target range of 100-150 mg/dl, and 69.8% were in the wider range of 70-180 mg/dl. The hypoglycemia (BG <40 mg/dl) rate was 0.18%. Conclusions: The CGS-SQ provided a means to deliver insulin in a standardized manner, resulting in satisfactory BG control with a low hypoglycemia rate, thus serving as a tool for safe and effective insulin therapy for hospitalized patients.

KW - Computers

KW - Diabetes

KW - Dosing

KW - Hyperglycemia

KW - Insulin

KW - Protocol

KW - Subcutaneous

UR - http://www.scopus.com/inward/record.url?scp=67649174350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649174350&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:67649174350

VL - 2

SP - 384

EP - 391

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 3

ER -